Development and Evaluation of Perfluorocarbon Nanobubbles for Apomorphine Delivery

Hwang, Tsong‐Long; Lin, Yin-Ku; Chi, Chen-Hsien; Huang, Tse-Hung; Fang, Jia‐You

doi:10.1002/jps.21687

Cited by 63 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultrasound trigger altered the release profiles on demand. Erythrocyte hemolysis study demonstrated the safety profile (<10% hemolysis) of PNs [100]. Altogether these studies revealed the potential of stimulus sensitive nano-carriers for improving stability, administration frequency and on-demand release kinetics of therapeutics against PD.…”

Section: Stimulus Responsive Nanoparticlesmentioning

confidence: 79%

“…The vascular imaging after intravenous injection of targeted MNPs confirm lactoferrin receptor mediated transcytosis with interaction between targeted nanoparticles and lactoferrin receptors expressed on microvascular endothelial cells [99]. Recently Hwang et al (2009) reported ultrasound responsive stable perfluorocarbon nanobubbles (PNs) loaded with dopamine receptor agonist (apomorphine) for targeting the brain. The studies showed the improved stability and higher plasma residence time of apomorphine loaded PNs in vivo attributable to rigid cholesterol and phospholipid membrane.…”

Section: Stimulus Responsive Nanoparticlesmentioning

confidence: 88%

See 1 more Smart Citation

Nanotechnology platforms in Parkinson’s Disease

2015

View full text Add to dashboard Cite

Parkinson's disease (PD) remains a serious concern due to its effects on the quality of life of patients and its socioeconomic burden to society. Present day management of PD has limitations in both diagnosis and treatment. Nanotechnology may provide smart solutions to this problem. The present review highlights the recent advancements in the development of nanotechnology platforms for PD. The review focuses on the use of such platforms in diagnostics, treatments, deep brain stimulation, neurosurgery and other

show abstract

Section: Stimulus Responsive Nanoparticlesmentioning

confidence: 79%

Section: Stimulus Responsive Nanoparticlesmentioning

confidence: 88%

Nanotechnology platforms in Parkinson’s Disease

2015

View full text Add to dashboard Cite

show abstract

“…20,[32][33][34] Therefore, the organic solvents could be completely removed under these conditions, and even if there were slight solvent residues, they did not affect the subsequent experiments.…”

Section: Physicochemical Characteristics Of Nanodroplets and Nqmentioning

confidence: 99%

“…Many of these particles were able to alter the distribution profiles of encapsulated drugs. 1,18 However, previous literature reports have indicated that these nanobubbles/nanodroplets are still in the early stages of development, 19,20 whether in ultrasonic imaging or therapeutic applications.…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies also used similar materials (coconut oil, perfluoropentane, and cholesterol) to produce nanodroplets, and the physical and chemical properties of the nanodroplets are consistent with our data. 20,36 The suitability of a formulation for clinical application depends on several conditions, and the development of formulations capable of efficiently carrying a payload is one of the most important goals of research. 48 Our data demonstrate that the NQ formulation achieved a near complete encapsulation efficiency of 99%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimaging

Chang¹,

Hou²,

Hung

et al. 2015

IJN

View full text Add to dashboard Cite

Bubble formulations have both diagnostic and therapeutic applications. However, research on nanobubbles/nanodroplets remains in the initial stages. In this study, a nanodroplet formulation was prepared and loaded with a novel class of chemotherapeutic drug, ie, quercetin, to observe its pharmacokinetic properties and ultrasonic bioimaging of specific sites, namely the abdominal vein and bladder. Four parallel groups were designed to investigate the effects of ultrasound and nanodroplets on the pharmacokinetics of quercetin. These groups were quercetin alone, quercetin triggered with ultrasound, quercetin-encapsulated in nanodroplets, and quercetin encapsulated in nanodroplets triggered with ultrasound. Spherical vesicles with a mean diameter of 280 nm were formed, and quercetin was completely encapsulated within. In vivo ultrasonic imaging confirmed that the nanodroplets could be treated by ultrasound. The results indicate that the initial 5-minute serum concentration, area under the concentration–time curve, elimination half-life, and clearance of quercetin were significantly enhanced by nanodroplets with or without ultrasound.

show abstract

Assessment of the biodistribution of an [¹⁸F]FDG‐loaded perfluorocarbon double emulsion using dynamic micro‐PET in rats

Fabiilli

Piert

Koeppe

et al. 2013

Contrast Media & Molecular

View full text Add to dashboard Cite

Perfluorocarbon (PFC) double emulsions loaded with a water-soluble, therapeutic agent can be triggered by ultrasound in a process known as acoustic droplet vaporization (ADV). Elucidating the stability and biodistribution of these sonosensitive vehicles and encapsulated agents are critical in developing targeted drug delivery strategies using ultrasound. [18F]fluorodeoxyglucose (FDG) was encapsulated in a PFC double emulsion and the in vitro diffusion of FDG was assessed using a Franz diffusion cell. Using dynamic micro positron emission tomography (micro-PET) and direct tissue sampling, the biodistribution of FDG administered as a solution (i.e. non-emulsified) or as an emulsion was studied in Fisher 344 rats (n = 6) bearing subcutaneous 9L gliosarcoma. Standardized uptake values (SUVs) and area under the curve of the SUV (AUCSUV) of FDG were calculated for various tissues. The FDG flux from the emulsion decreased by up to a factor of 6.9 compared to the FDG solution. FDG uptake, calculated from the AUCSUV, decreased by 36% and 44% for brain and tumor, respectively, when comparing FDG solution versus FDG emulsion (p < 0.01). Decreases in AUCSUV in highly metabolic tissues such as brain and tumor demonstrated retention of FDG within the double emulsion. No statistically significant differences in lung AUCSUV were observed, suggesting minimal accumulation of the emulsion in the pulmonary capillary bed. The liver AUCSUV increased by 356% for the FDG emulsion, thus indicating significant hepatic retention of the emulsion.

show abstract

Development and Evaluation of Perfluorocarbon Nanobubbles for Apomorphine Delivery

Cited by 63 publications

References 40 publications

Nanotechnology platforms in Parkinson’s Disease

Nanotechnology platforms in Parkinson’s Disease

Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimaging

Assessment of the biodistribution of an [¹⁸F]FDG‐loaded perfluorocarbon double emulsion using dynamic micro‐PET in rats

Contact Info

Product

Resources

About

Development and Evaluation of Perfluorocarbon Nanobubbles for Apomorphine Delivery

Cited by 63 publications

References 40 publications

Nanotechnology platforms in Parkinson’s Disease

Nanotechnology platforms in Parkinson’s Disease

Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and&nbsp;their&nbsp;use for bioimaging

Assessment of the biodistribution of an [18F]FDG‐loaded perfluorocarbon double emulsion using dynamic micro‐PET in rats

Contact Info

Product

Resources

About

Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimaging

Assessment of the biodistribution of an [¹⁸F]FDG‐loaded perfluorocarbon double emulsion using dynamic micro‐PET in rats